指南与共识心力衰竭与心肌病高血压心律失常

国际心脏肿瘤学会共识:定义癌症治疗的心血管毒性

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
指南 / 共识 · Eur Heart J · 2022-01-01

该共识由国际心脏肿瘤学会(IC-OS)制定,针对癌症治疗相关心血管毒性缺乏统一定义的问题,提供了心肌病/心力衰竭与心肌炎、血管毒性、高血压、心律失常及 QTc 延长的共识定义。文件旨在为临床和未来研究提供定义框架,并强调需将定义与临床实践结局及临床试验心血管终点关联。

要点

  • 共识统一了癌症治疗相关心血管毒性的定义,涵盖心肌病/心衰、心肌炎、血管毒性、高血压、心律失常和 QTc 延长。
  • 此前研究因心血管毒性终点不统一难以直接比较,临床理解差异也导致管理差异。
  • 共识定义服务于临床和研究,需与临床结局和试验终点关联以改善癌症患者心血管预后。

核心结论

  • IC-OS 共识为最常见报告的心血管毒性提供统一定义,以促进临床管理和跨学科交流。

研究设计与样本

  • 该文件为国际心脏肿瘤学会(IC-OS)共识声明,基于对当前心血管毒性领域及所用定义的协调性综述。

主要发现

  • 许多研究评估了不同癌症治疗患者的心血管毒性,但因心血管毒性终点缺乏统一性而难以直接比较。
  • 临床实践中对心血管毒性构成的理解存在显著差异,可导致患者管理和结局的显著变化。

关键数值与推荐

  • 共识定义涵盖心肌病/心力衰竭与心肌炎、血管毒性、高血压、心律失常及 QTc 延长。

临床怎么用

  • 共识定义可用于临床中界定心血管毒性,并为未来研究提供结构。
  • 需将共识定义与临床实践结局及临床试验心血管终点关联。
  • 应促进不同学科间沟通以改善癌症合并心血管疾病患者的临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Herrmann, Lenihan, Armenian, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022. PMID: 34904661. doi:10.1093/eurheartj/ehab674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。